Brind.

Addex Therapeutics and Indivior are partnering on a drug candidate.

Steady: 0 in the last 7 days Updated sep 28

The latest in this situation

  1. Indivior gave up GABAB PAM rights to Addex Therapeutics.
  2. Indivior and Addex Therapeutics regained full global rights to GABAB PAM assets.

How it started

3 reports, 1 independent, last reported Sep 24. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Addex Therapeutics and Indivior are partnering on a drug candidate.

Who's involved

What this event is mainly about
IndiviorAddex Therapeutics

How it developed

Newest first. Tap a step to see who reported it.
  1. Indivior and Addex Therapeutics regained full global rights to GABAB PAM assets.Sub-event
  2. The partnership between Indivior and Addex Therapeutics focuses on a GABAB PAM candidate.1 source
  3. Partnership formed between Addex Therapeutics and Indivior regarding a drug candidate.1 source

Keep exploring

The entities involved

  • Indivior

    specialty pharmaceuticals business headquartered in Richmond, Virginia

    Nothing else this week.

  • Addex Therapeutics

    Swiss public company

    Nothing else this week.

Coverage

Newest first; wire copies grouped